Advertisement
Home Tags Prescription Drugs

Tag: Prescription Drugs

In treatment following acute coronary syndrome

Statin + Ezetimibe May Benefit After Acute Coronary Syndrome

0
Lowering of LDL cholesterol levels, improved cardiovascular outcomes for simvastatin + ezetimibe
For veterans regularly prescribed angiotensin receptor blockers (ARBs) admitted for noncardiac surgery

Withholding ARBs After Surgery Linked to Higher Mortality

0
Failure to resume ARBs linked to mortality risk, especially in younger patients
Chronic omega-3 fatty acid supplementation has an additive effect when combined with acute dosages of morphine in an animal model

Omega-3s May Be Useful Adjunct to Opioids in Pain Therapy

0
Omega-3 may reduce side effects, development of morphine tolerance
Although most Medicare Part D plans cover at least one biologic disease-modifying antirheumatic drug

Most Part D Plans Cover at Least One Biologic DMARD

0
In most plans, patients required to pay coinsurance percentage, averaging 29.6 percent of drug costs
Youth prescribed antipsychotic medication should be monitored for exaggerated weight gain

Review: Monitor Weight for Youth on Antipsychotics

0
SSRIs and SNRIs may improve weight status in short term, but not long term
The drug elotuzumab reduces the risk of cancer progression and mortality by 30 percent when combined with the standard two-drug therapy for multiple myeloma

ASCO: Elotuzumab Shows Benefit in Multiple Myeloma

0
Survival gains when elotuzumab was added to treatment
Adding palbociclib (Ibrance) to standard hormone therapy may benefit patients with advanced hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer over hormone therapy alone

ASCO: Palbociclib Ups Survival in HR+ Metastatic Breast Cancer

0
Adding palbociclib to standard hormone therapy kept disease from progressing for nine months
Not all melanoma patients need surgery to remove lymph nodes surrounding their tumor

ASCO: Lymph Node Sx Doesn’t Benefit All Melanoma Patients

0
Second study supports new immunotherapy for enhanced survival in advanced melanoma
Two new targeted treatments have shown promise in slowing the progression of recurring chronic-lymphocytic leukemia and slow-growing non-Hodgkin's lymphoma

ASCO: Rx Strategies Promising for CLL, Non-Hodgkin’s Lymphoma

0
Ibrutinib, obinutuzumab slow progression of CLL, non-Hodgkin's lymphoma
The first genetic marker to predict response to pembrolizumab (Keytruda) has been identified by researchers

ASCO: MMR Deficiency Predicts Pembrolizumab Response

0
Findings may help doctors better choose patients to receive pembrolizumab (Keytruda)